Holen Sie sich die Stockscreener-App
1.46
4.29%
0.06
Handel nachbörslich:
1.45
-0.01
-0.68%
Akebia Therapeutics Inc Aktie (AKBA) Neueste Nachrichten
Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights - GuruFocus
Akebia Therapeutics, Inc. (AKBA) Shareholders Greenlight 18.9 Million Share Increase - MSN
Akebia Therapeutics Details Vafseo Commercial Push, TIW Dosing Plans and Kidney Pipeline at Leerink Conference - Yahoo Finance
Akebia at Leerink Conference: Strategic Focus on Vafseo and Pipeline By Investing.com - Investing.com Canada
How The Akebia Therapeutics (AKBA) Story Is Shifting As Vafseo Revenue Assumptions Reset - Yahoo Finance
Akebia Therapeutics Stock Slumps After FDA Meeting Ends Without Path Forward for Vafseo Label Expansion - MSN
Akebia Therapeutics (NASDAQ:AKBA) CEO John Butler Purchases 69,270 Shares - MarketBeat
Layoff Watch: Does Akebia Therapeutics Inc offer margin of safety2025 Fundamental Recap & Safe Entry Zone Tips - baoquankhu1.vn
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Short Interest Update - MarketBeat
Citigroup Inc. Has $5.23 Million Position in Akebia Therapeutics, Inc. $AKBA - MarketBeat
Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference - The Globe and Mail
Akebia Therapeutics Reports Inducement Grants - National Today
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
AKBA Shares Rise On Clinical Pipeline Optimism As Anemia Drug Gains Traction - Stocktwits
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), QuidelOrtho (QDEL) and Akebia Therapeutics (AKBA) - The Globe and Mail
Akebia Therapeutics (NASDAQ:AKBA) Lowered to "Strong Sell" Rating by Zacks Research - MarketBeat
Wall Street Zen Downgrades Akebia Therapeutics (NASDAQ:AKBA) to Hold - MarketBeat
Akebia Therapeutics, Inc. (AKBA) Stock Analysis: A Potential 233% Upside in the Healthcare Sector - DirectorsTalk Interviews
Akebia Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q4 2025 Earnings Call Transcript - Insider Monkey
Akebia Therapeutics (AKBA) Loss In Q4 2025 Tests Bullish Margin Narratives - simplywall.st
Akebia Therapeutics Inc (AKBA) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Challenges - GuruFocus
Akebia Therapeutics, Inc. posts full year 2025 financial results amid commercial and pipeline expansion - Traders Union
Key facts: Akebia Therapeutics reports 47% revenue rise; Phase 2 trials planned - TradingView
Akebia (AKBA) Q4 2025 Earnings Call Transcript - AOL.com
Akebia Therapeutics (NASDAQ:AKBA) Releases Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Akebia Therapeutics Q4 2025 Earnings Call Insights - Intellectia AI
Akebia Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Akebia Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
AKBA: Vafseo launch drove 50% revenue growth in 2025, with expanding adoption and robust cash reserves - TradingView
Akebia Therapeutics Q4 Earnings Call Highlights - MarketBeat
Akebia Therapeutics Inc (NASDAQ:AKBA) Reports Q4 Revenue Beat and 49% Annual Growth Amid Mixed Market Reaction - ChartMill
Akebia (AKBA) Reports Strong Q4 Revenue and Positive Outlook for Vafseo - GuruFocus
AKEBIA THERAPEUTICS ($AKBA) Releases Q4 2025 Earnings - Quiver Quantitative
Akebia Therapeutics, Inc. Q4 Loss Decreases - Nasdaq
Akebia Therapeutics, Inc. SEC 10-K Report - TradingView
AKBA: Revenue surged 47% to $236.2M in 2025, with Vafseo launch and pipeline expansion offsetting Auryxia LoE - TradingView
Akebia Therapeutics: Q4 Earnings Snapshot - Barchart.com
[8-K] Akebia Therapeutics, Inc. Reports Material Event | AKBA SEC FilingForm 8-K - Stock Titan
Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights - The Manila Times
AKBA: Strong 2025 revenue growth and improved margins set the stage for Vafseo-led expansion in 2026 - TradingView
Analysts Conflicted on These Healthcare Names: Akebia Therapeutics (AKBA), Idexx Laboratories (IDXX) and Arvinas Holding Company (ARVN) - The Globe and Mail
Uncovering Potential: Akebia Therapeutics's Earnings Preview - Benzinga
BTIG Research Has Lowered Expectations for Akebia Therapeutics (NASDAQ:AKBA) Stock Price - MarketBeat
Where Akebia Therapeutics Stands With Analysts - Benzinga
BTIG Maintains Buy Rating on AKBA, Lowers Price Target by 20% | AKBA Stock News - GuruFocus
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Akebia Therapeutics, Inc. (AKBA): Investor Outlook Reveals 289.83% Potential Upside - DirectorsTalk Interviews
Akebia Therapeutics (AKBA) to Release Quarterly Earnings on Thursday - MarketBeat
Piper Sandler Lowers Akebia Therapeutics (AKBA) PT to $4 as Firm Updates Estimates Following Year-End Reports - Yahoo Finance
Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights - The Globe and Mail
Akebia Therapeutics to Report Fourth Quarter and Full Year - GlobeNewswire
MSN Money - MSN
Quarterly Earnings: How strong is Akebia Therapeutics Inc. stock balance sheetJuly 2025 Closing Moves & Weekly Top Gainers Trade List - mfd.ru
1.15%
3.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):